Europe LAMEA Oncology/Anti-cancer drugs Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 LAMEA Oncology/Anti-cancer drugs Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Oral Therapy Market Performance (Volume)
  • 2.1.2 Injectable Therapy Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Oral Therapy Market Performance (Value)
  • 2.1.2 Injectable Therapy Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Chemotherapy Market Performance (Volume)
  • 3.1.2 Targeted Therapy Market Performance (Volume)
  • 3.1.3 Immunotherapy (Biologic Therapy) Market Performance (Volume)
  • 3.1.4 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Amgen
  • 4.1.1 Amgen Profiles
  • 4.1.2 Amgen Product Information
  • 4.1.3 Amgen LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.1.4 Amgen LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.2 AstraZeneca
  • 4.2.1 AstraZeneca Profiles
  • 4.2.2 AstraZeneca Product Information
  • 4.2.3 AstraZeneca LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.2.4 AstraZeneca LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.3 Roche Diagnostics
  • 4.3.1 Roche Diagnostics Profiles
  • 4.3.2 Roche Diagnostics Product Information
  • 4.3.3 Roche Diagnostics LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.3.4 Roche Diagnostics LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.4 GlaxoSmithKline
  • 4.4.1 GlaxoSmithKline Profiles
  • 4.4.2 GlaxoSmithKline Product Information
  • 4.4.3 GlaxoSmithKline LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.4.4 GlaxoSmithKline LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.5 Merck & Co.
  • 4.5.1 Merck & Co. Profiles
  • 4.5.2 Merck & Co. Product Information
  • 4.5.3 Merck & Co. LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.5.4 Merck & Co. LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.6 Novartis
  • 4.6.1 Novartis Profiles
  • 4.6.2 Novartis Product Information
  • 4.6.3 Novartis LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.6.4 Novartis LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.7 AbbVie
  • 4.7.1 AbbVie Profiles
  • 4.7.2 AbbVie Product Information
  • 4.7.3 AbbVie LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.7.4 AbbVie LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.8 Sanofi
  • 4.8.1 Sanofi Profiles
  • 4.8.2 Sanofi Product Information
  • 4.8.3 Sanofi LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.8.4 Sanofi LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.9 EIMC United Pharmaceuticals
  • 4.9.1 EIMC United Pharmaceuticals Profiles
  • 4.9.2 EIMC United Pharmaceuticals Product Information
  • 4.9.3 EIMC United Pharmaceuticals LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.9.4 EIMC United Pharmaceuticals LAMEA Oncology/Anti-cancer drugs Business Development and Market Status
• 4.10 Actavis plc.
  • 4.10.1 Actavis plc. Profiles
  • 4.10.2 Actavis plc. Product Information
  • 4.10.3 Actavis plc. LAMEA Oncology/Anti-cancer drugs Business Performance
  • 4.10.4 Actavis plc. LAMEA Oncology/Anti-cancer drugs Business Development and Market Status

5 Market Performance for Manufacturers

• 5.1 Europe LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 LAMEA Oncology/Anti-cancer drugs Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe LAMEA Oncology/Anti-cancer drugs Market Performance (Sales Point)

• 7.1 Europe LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe LAMEA Oncology/Anti-cancer drugs Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe LAMEA Oncology/Anti-cancer drugs Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain LAMEA Oncology/Anti-cancer drugs Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Chemotherapy Industry
• 11.2 Targeted Therapy Industry
• 11.3 Immunotherapy (Biologic Therapy) Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Oral Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Injectable Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Chemotherapy Sales and and Growth Rate 2019-2024
  • 12.4.3 Targeted Therapy Sales and and Growth Rate 2019-2024
  • 12.4.4 Immunotherapy (Biologic Therapy) Sales and and Growth Rate 2019-2024
  • 12.4.5 Others Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe LAMEA Oncology/Anti-cancer drugs Gross Profit Trend 2019-2024

13 Conclusion